Nurix Therapeutics, Inc.

Equities

NRIX

US67080M1036

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-07-12 EDT 5-day change 1st Jan Change
23.82 USD +8.13% Intraday chart for Nurix Therapeutics, Inc. +22.34% +130.81%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Needham Adjusts Price Target on Nurix Therapeutics to $29 From $31, Maintains Buy Rating MT
RBC Lifts Price Target on Nurix Therapeutics to $27 From $26, Keeps Outperform, Speculative Risk MT
Nurix Therapeutics Q2 Loss Widens Amid Revenue Decline MT
Nurix Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2024 CI
Earnings Flash (NRIX) NURIX THERAPEUTICS Reports Q2 Revenue $12.1M MT
Nurix Therapeutics, Inc.(NasdaqGM:NRIX) added to Russell Microcap Growth Index CI
Nurix Therapeutics, Inc.(NasdaqGM:NRIX) added to Russell 3000E Growth Index CI
Nurix Therapeutics, Inc.(NasdaqGM:NRIX) added to Russell 3000 Growth Index CI
Nurix Therapeutics, Inc.(NasdaqGM:NRIX) added to Russell 2000 Growth Index CI
Nurix Therapeutics, Inc.(NasdaqGM:NRIX) added to Russell 2500 Growth Index CI
Nurix Therapeutics, Inc.(NasdaqGM:NRIX) added to Russell Small Cap Comp Growth Index CI
RBC Raises Price Target on Nurix Therapeutics to $26 From $23, Maintains Outperform, Speculative Risk MT
Nurix Therapeutics Insider Sold Shares Worth $400,216, According to a Recent SEC Filing MT
HC Wainwright Raises Price Target on Nurix Therapeutics to $26 From $19, Maintains Buy Rating MT
JPMorgan Adjusts Price Target on Nurix Therapeutics to $31 From $30, Maintains Overweight Rating MT
Sector Update: Health Care Stocks Decline Premarket Monday MT
Investors Look for Fresh Impetus Ahead of Holiday Break, Stifling US Equity Futures Pre-Bell MT
Sector Update: Health Care MT
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Monday Ahead of More Economic Data MT
Top Premarket Gainers MT
Nurix Therapeutics Says Patients Respond Well to Potential Non-Hodgkin Lymphoma Treatment in Phase 1 Trial MT
Transcript : Nurix Therapeutics, Inc. - Special Call
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia At the European Hematology Association Congress CI
Nurix Therapeutics Files Mixed Shelf Registration MT
Certain Restricted Stock Units of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-JUN-2024. CI
Chart Nurix Therapeutics, Inc.
More charts
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
23.82 USD
Average target price
28.17 USD
Spread / Average Target
+18.25%
Consensus
  1. Stock Market
  2. Equities
  3. NRIX Stock
  4. News Nurix Therapeutics, Inc.
  5. Sector Update: Health Care Stocks Decline Premarket Monday